tiprankstipranks
Trending News
More News >
Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) AI Stock Analysis

Compare
1,294 Followers

Top Page

GL

Galmed Pharmaceuticals

(NASDAQ:GLMD)

Rating:28Underperform
Price Target:
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
Positive Factors
Market Opportunities
Targeting international markets where semaglutide is not meaningfully patent-protected presents significant market opportunities for Galmed.
Partnerships
Galmed has partnered with Virginia Commonwealth University to evaluate Aramchol’s potential in oncology indications.
Negative Factors
Clinical Trials
The company halted the Phase 3 trial for Aramchol meglumine due to financial and enrollment issues.
Strategic Uncertainty
Galmed's strategic positioning and path forward remains unclear.

Galmed Pharmaceuticals (GLMD) vs. SPDR S&P 500 ETF (SPY)

Galmed Pharmaceuticals Business Overview & Revenue Model

Company DescriptionGalmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
How the Company Makes MoneyGalmed Pharmaceuticals makes money primarily through the development and potential commercialization of its lead product candidate, Aramchol. As a clinical-stage company, Galmed does not currently generate product revenues. Instead, the company relies on funding from public and private investors to finance its research and development activities. In the future, Galmed aims to generate revenue through the successful commercialization of Aramchol, which could include sales, licensing agreements, or partnerships with larger pharmaceutical companies. Collaborations and partnerships could provide upfront payments, milestone payments, and royalties based on sales performance once Aramchol or any other product candidates receive regulatory approval and are brought to market.

Galmed Pharmaceuticals Financial Statement Overview

Summary
Galmed Pharmaceuticals exhibits a challenging financial outlook. The company reports zero revenue, leading to increasing net losses and negative profit margins. While the balance sheet shows no debt and strong equity, the negative cash flow and reliance on equity financing pose significant risks to sustainability.
Income Statement
10
Very Negative
Galmed Pharmaceuticals has consistently reported zero revenue, which severely impacts its profitability. The company has faced increasing net losses over the years, with a significant negative net profit margin. Both EBIT and EBITDA margins are deeply negative, reflecting poor operational performance.
Balance Sheet
25
Negative
The company maintains a strong equity position with no debt, resulting in a favorable debt-to-equity ratio. However, the absence of revenue and continuous losses undermine the return on equity, which remains negative. The equity ratio is high, indicating reliance on equity financing.
Cash Flow
20
Very Negative
Galmed Pharmaceuticals shows a negative free cash flow, consistently higher operating cash outflows than net income, indicating operational inefficiencies. The company relies heavily on external financing, as seen in the positive financing cash flow.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit-83.00K-31.00K-35.00K-42.00K-39.00K
EBITDA-7.42M-6.87M-17.62M-32.84M-30.17M
Net Income-7.52M-6.91M-18.57M-31.95M-27.61M
Balance Sheet
Total Assets18.50M16.63M16.56M36.60M52.38M
Cash, Cash Equivalents and Short-Term Investments15.33M12.64M13.79M34.81M50.89M
Total Debt0.0041.00K44.00K229.00K216.00K
Total Liabilities2.17M2.75M3.14M6.11M8.23M
Stockholders Equity16.33M13.88M13.42M30.50M44.15M
Cash Flow
Free Cash Flow-5.88M-6.14M-18.50M-32.90M-26.33M
Operating Cash Flow-5.88M-6.14M-18.50M-32.89M-26.29M
Investing Cash Flow-1.11M800.00K17.56M11.46M16.54M
Financing Cash Flow8.79M6.18M70.00K17.37M768.00K

Galmed Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.09
Price Trends
50DMA
1.53
Positive
100DMA
1.71
Positive
200DMA
2.68
Negative
Market Momentum
MACD
0.11
Negative
RSI
72.07
Negative
STOCH
68.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLMD, the sentiment is Positive. The current price of 2.09 is above the 20-day moving average (MA) of 1.77, above the 50-day MA of 1.53, and below the 200-day MA of 2.68, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 72.07 is Negative, neither overbought nor oversold. The STOCH value of 68.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLMD.

Galmed Pharmaceuticals Risk Analysis

Galmed Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. Galmed Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Galmed Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.45B0.30-61.93%2.28%16.62%1.04%
45
Neutral
$4.68M-192.85%-100.00%5.43%
ININM
44
Neutral
$3.30M-91.71%-11.94%56.72%
29
Underperform
$4.30M-91.32%48.81%
28
Underperform
$4.13M-49.58%71.41%
$790.29K-288.06%
25
Underperform
$5.22M-138.80%42.26%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GLMD
Galmed Pharmaceuticals
2.09
-1.47
-41.29%
MTNB
Matinas BioPharma
0.95
-7.20
-88.34%
HEPA
Hepion Pharmaceuticals
0.06
-51.94
-99.88%
QNRX
Quoin Pharmaceuticals
8.73
-12.20
-58.29%
INM
InMed Pharmaceuticals
2.76
-2.14
-43.67%
GLTO
Galecto
3.32
-9.32
-73.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 30, 2025